Back to Search
Start Over
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
- Source :
- Blood Cancer Journal, Blood Cancer Journal, Vol 11, Iss 1, Pp 1-4 (2021)
- Publication Year :
- 2020
-
Abstract
- No abstract available
- Subjects :
- Ruxolitinib
medicine.medical_specialty
Humans
Janus Kinases
Multivariate Analysis
Primary Myelofibrosis
Protein Kinase Inhibitors
Pyrazoles
Risk Factors
Treatment Outcome
medicine.medical_treatment
Splenectomy
lcsh:RC254-282
Nitriles
Pyrimidines
Ruxolitinib discontinuation syndrome, risk factors, myelofibrosis
NO
Myeloproliferative disease
Internal medicine
Correspondence
medicine
Risk factor
Bone pain
Myelofibrosis
Respiratory distress
business.industry
Incidence (epidemiology)
Hematology
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Discontinuation
Oncology
medicine.symptom
business
Haematological diseases
medicine.drug
Subjects
Details
- ISSN :
- 20445385
- Volume :
- 11
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Blood cancer journal
- Accession number :
- edsair.doi.dedup.....6a62daabaefd684de2397c145f15acef